Duobrii (halobetasol propionate/tazarotene) topical lotion — coverage criteria
Customize your policy alerts
Sign up for Health Net Policy CP PMN.208 alerts
Get alerted when Policy CP PMN.208 changes without checking for updates manually.
Monitor payer policy activity
Policy governs medical necessity criteria, prior authorization, and coverage limits for Duobrii topical lotion for plaque psoriasis in adults across Health Net lines of business covered by this policy.
Step therapy bypass for Illinois HIM per IL HB 5395 was added (step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026).
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met for initial approval:
Approval duration: 12 months
Continuation Therapy
Covered for continued therapy when ALL of the following are met:
Approval duration: 12 months
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the referenced off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP PMN.53 for Medicaid) or other applicable evidence of coverage documentation.
Use of this product is contraindicated in pregnancy. Providers should not initiate therapy in pregnant patients and must document pregnancy status when relevant to coverage decisions.
Requests for use outside the FDA‑approved indication require submission of supporting clinical documentation. If the request does not include adequate evidence of efficacy and safety per the applicable off‑label use policy (see CP.CPA.09, HIM.PA.154, CP PMN.53), the request will be considered not authorized / medical necessity not met.
Coding and Limits
| CP PMN.208 | Policy reference number (document identifier) |
Provider Actions / Prior Authorization
Prior Authorization Required
Prior authorization is required. Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all initial approval criteria for coverage.
- Approval duration: 12 months
- Dose limit: does not exceed 100 g per month (one tube per month)
Step Therapy (IL HIM Bypass)
Step therapy requirements apply for initial approval: members must have failed specified generic topical agents (e.g., halobetasol propionate and clobetasol propionate, and tazarotene) unless these agents are contraindicated or cause clinically significant adverse effects. For Illinois HIM requests only, the step therapy requirements do not apply as of 2026-01-01 per IL HB 5395 — providers should note the operational bypass for HIM members.
- Step therapy failures required unless contraindicated or adverse effects documented
- Illinois HIM bypass effective 2026-01-01 per IL HB 5395
Required Documentation
Provider must submit supporting clinical documentation with the prior authorization request. Acceptable documentation includes office/chart notes, relevant lab results, consultation notes, and any other clinical information demonstrating the member meets all listed criteria.
- Include documentation of step therapy trials or reason for bypass (e.g., contraindication, adverse effects)
- Include documentation of diagnosis, body surface area involvement, prescribing clinician specialty (dermatologist or rheumatologist), and dosing
Documentation/Indication Not Supported — Denial Risk
Requests lacking required documentation or requests for non‑covered/unapproved indications may be denied. If the indication is non‑FDA approved, provide sufficient evidence of efficacy and safety per applicable off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for HIM, CP PMN.53 for Medicaid) or applicable evidence of coverage documents.
- Denial risk if documentation of step therapy trials, contraindications, or diagnosis severity (BSA) is missing
- Non‑FDA approved indications require supporting evidence per listed off‑label policies
Drug Definitions and Comparators
Background
Duobrii lotion is a fixed‑dose topical combination containing halobetasol propionate (a high‑potency corticosteroid) and tazarotene (a topical retinoid). It is indicated for the topical treatment of plaque psoriasis in adults and is supplied as a 100 g tube. Typical administration is once‑daily application of a thin layer to affected areas until control is achieved; dosing guidance in this policy limits total use to no more than 100 g per month (one 100 g tube).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.